BIOMAT Database Logo BIOMAT Database Logo

Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels. 1979

P J Orsulak, and J J Schildkraut

A brief review of the literature surrounding the relationship between plasma levels of tricyclic antidepressants currently available in the United States and clinical efficacy is presented. While therapeutic ranges for plasma levels of some tricyclic antidepressants are reasonably well established, the relationships between plasma levels of others and clinical efficacy require further clarification. Conditions under which plasma level measurements are clinically useful and factors that alter steady-state plasma levels are discussed.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008991 Monitoring, Physiologic The continuous measurement of physiological processes, blood pressure, heart rate, renal output, reflexes, respiration, etc., in a patient or experimental animal; includes pharmacologic monitoring, the measurement of administered drugs or their metabolites in the blood, tissues, or urine. Patient Monitoring,Monitoring, Physiological,Physiologic Monitoring,Monitoring, Patient,Physiological Monitoring
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003891 Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Desmethylimipramine,Apo-Desipramine,Demethylimipramine,Desipramine Hydrochloride,Norpramin,Novo-Desipramine,Nu-Desipramine,PMS-Desipramine,Pertofran,Pertofrane,Pertrofran,Petylyl,Ratio-Desipramine,Apo Desipramine,Hydrochloride, Desipramine,Novo Desipramine,Nu Desipramine,PMS Desipramine,Ratio Desipramine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000639 Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines. Amineurin,Amitrip,Amitriptylin Beta,Amitriptylin Desitin,Amitriptylin RPh,Amitriptylin-Neuraxpharm,Amitriptyline Hydrochloride,Amitrol,Anapsique,Apo-Amitriptyline,Damilen,Domical,Elavil,Endep,Laroxyl,Lentizol,Novoprotect,Saroten,Sarotex,Syneudon,Triptafen,Tryptanol,Tryptine,Tryptizol,Amitriptylin Neuraxpharm,Apo Amitriptyline,Desitin, Amitriptylin,RPh, Amitriptylin
D000929 Antidepressive Agents, Tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system. Antidepressants, Tricyclic,Tricyclic Antidepressant,Tricyclic Antidepressant Drug,Tricyclic Antidepressive Agent,Tricyclic Antidepressive Agents,Antidepressant Drugs, Tricyclic,Agent, Tricyclic Antidepressive,Agents, Tricyclic Antidepressive,Antidepressant Drug, Tricyclic,Antidepressant, Tricyclic,Antidepressive Agent, Tricyclic,Drug, Tricyclic Antidepressant,Drugs, Tricyclic Antidepressant,Tricyclic Antidepressant Drugs,Tricyclic Antidepressants

Related Publications

P J Orsulak, and J J Schildkraut
Monitoring tricyclic antidepressant plasma levels.
May 1984, American family physician,
P J Orsulak, and J J Schildkraut
Indications and guidelines for plasma tricyclic antidepressant concentration monitoring.
March 1981, Journal of clinical psychopharmacology,
P J Orsulak, and J J Schildkraut
Therapeutic implications of tricyclic antidepressant plasma levels.
June 1976, The Journal of nervous and mental disease,
P J Orsulak, and J J Schildkraut
Monitoring tricyclic antidepressant plasma concentrations.
June 1979, JAMA,
P J Orsulak, and J J Schildkraut
[Therapeutic monitoring of tricyclic antidepressant drugs].
January 2003, Psychiatria polska,
P J Orsulak, and J J Schildkraut
Relevancy of tricyclic antidepressant plasma levels.
April 1981, The American journal of psychiatry,
P J Orsulak, and J J Schildkraut
Plasma level monitoring of tricyclic antidepressant therapy.
January 1977, Clinical pharmacokinetics,
P J Orsulak, and J J Schildkraut
Tricyclic antidepressant plasma levels in overdose.
February 1981, JAMA,
P J Orsulak, and J J Schildkraut
Benzodiazepines and tricyclic antidepressant plasma levels.
July 1973, British medical journal,
P J Orsulak, and J J Schildkraut
Clinical significance of tricyclic antidepressant plasma levels.
November 1979, Psychosomatics,
Copied contents to your clipboard!